Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
0,10 RT
COOOLLL Bid 0.03 Ask 2,000.00
Caraustar Industries, Inc. ( CSAR) Short Interest
CSAR
Caraustar Industries, Inc.NASDAQ-GM
Settlement Date Short Interest Avg Daily Share Volume Days To Cover
2/27/2009 93,028 436,398 1.000000
2/13/2009 111,423 47,215 2.359907
1/30/2009 40,163 101,864 1.000000
1/15/2009 42,841 17,754 2.413034
12/31/2008 44,838 58,748 1.000000
12/15/2008 62,661 132,840 1.000000
11/28/2008 57,755 52,289 1.104534
11/14/2008 60,400 85,635 1.000000
10/31/2008 46,275 101,635 1.000000
10/15/2008 260,468 36,662 7.104577
9/30/2008 276,205 33,642 8.210124
9/15/2008 293,253 40,062 7.319979
8/29/2008 313,240 102,586 3.053438
8/15/2008 316,508 130,041 2.433909
7/31/2008 408,776 118,733 3.442817
7/15/2008 418,408 86,019 4.864135
6/30/2008 1,185,597 133,675 8.869250
6/13/2008 1,182,387 125,599 9.413984
5/30/2008 1,566,213 112,918 13.870357
5/15/2008 1,597,056 200,716 7.956795
4/30/2008 748,056 97,071 7.706277
4/15/2008 828,946 174,357 4.754303
3/31/2008 1,247,780 372,388 3.350752
3/14/2008 1,090,356 219,005 4.978681
See also: Short Interest data entry page
RESISTANCE ABOVE
+70% at 0.17 ± 0.02, type double, strength 10 ->ok
+110% at 0.21 ± 0.03, type single, strength 8 ->ok
+200% at 0.3 ± 0.04, type double, strength 4 -> ok
+330% at 0.43 ± 0.06, type triple+, strength 10 -> ok
+530% at 0.63 ± 0.09, type double, strength 6 -> ok
+1290% at 1.39 ± 0.2, type single, strength 8->
+1600% at 1.7 ± 0.24, type double, strength 4
+2060% at 2.16 ± 0.3, type triple, strength 10
I hope, i have 200k
Next week we see $.50
Why is the price so low ????
Short Interest (Shares Short) 93,000
Days To Cover (Short Interest Ratio) 0.2
Short Percent of Float 0.33 %
Short Interest - Prior 111,400
Short % Increase / Decrease -16.52 %
Short Squeeze Ranking™ -0
% From 52-Wk High ($ 3.17 ) -6791.30 %
% From 52-Wk Low ($ 0.01 ) 78.26 %
% From 200-Day MA ($ 0.70 ) -1421.74 %
% From 50-Day MA ($ 0.15 ) -226.09 %
Price % Change (52-Week) -99.00 %
Shares Float 28,580,000
Total Shares Outstanding 29,545,136
% Owned by Insiders 3.61 %
% Owned by Institutions 60.70 %
Market Cap. $ 1,359,076
Trading Volume - Today 4,137,550
Trading Volume - Average 436,400
Trading Volume - Today vs. Average 948.11 %
Earnings Per Share -2.89
PE Ratio
Record Date 2009-MarA
Sector Consumer Goods
Industry Paper & Paper Products
Exchange NAS
How many Shares are Short ???
I buy more on 40
Gap Close and 0,79
79 cent today!!!!!!!!!!!!!!!!
50+ cent, here wecome
L2, Please
$ 0,40 Open Today?
highest volume in 2 years 4 $we come
Generex Biotechnology Announces Successful Phase III Study Data for Generex Oral-lyn(tm)
3/10/2009 9:30:27 AM - GlobeNewswire
WORCESTER, Mass., Mar 10, 2009 (GlobeNewswire via COMTEX News Network) --
Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced positive results following the review of the Phase III data for the Company's flagship product, Generex Oral-lyn, a proprietary oral insulin spray product designed to replace prandial injections of insulin.
Generex, together with the Company's independent third party statistical and data monitoring consultants, will continue to monitor the ongoing pivotal Phase III Generex Oral-lyn study according to protocol and national/international ICH-GCPs. To date, more than 300 subjects have been enrolled in the study (with 60 subjects having achieved the requisite six-month treatment milestone) and the product's non-inferiority to injectable meal-time (prandial) insulin appears to be maintained. If the current positive trend is maintained, then a large reduction of required enrollment will suffice for formal verification of the non-inferiority hypothesis.
The current data also demonstrates that no significant Generex Oral-lyn drug-related "Adverse Events" or "Serious Adverse Events" have been reported, which also supports the current initiatives of the study.
"The current data and trends represent a critical milestone for the Company," said Anna Gluskin, Generex's President and Chief Executive Officer. "These results are consistent with the results of our previous studies. This will allow us greater flexibility in our strategies for filing submissions with regulatory authorities in major global markets and other jurisdictions where applications are already in progress."
The Company believes that Generex Oral-lyn will offer a safe, simple, fast, effective and pain-free alternative to prandial insulin injections which will improve patient compliance with therapeutic regimes thereby delaying the progress of diabetes and the onset of its myriad complications.
About Generex Biotechnology Corporation
Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in India and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. For more information, visit the Generex website at http://www.generex.com.
The Generex Biotechnology Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3831
Safe Harbor Statement
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Generex Biotechnology Corp.
American Capital Ventures, Inc. Howard Gostfrand 1-877-918-0774
(C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.
L2, Please!
World's No. 1 Hacker Gregory Evans Shows Students That Crime Does Pay
ATLANTA, GA -- (Marketwire) -- 03/04/09 -- CEO of LIGATT Security (PINKSHEETS: IGTP) Gregory Evans announced today that the company will launch a series of cyber-crime related courses at the beginning of this month. The courses will be taught at the Jasper, Woodstock and North Metro campuses of Appalachian Technical College in the metro Atlanta area.
Self proclaimed, "World's No. 1 Hacker," Gregory Evans will use his expertise combined with over 25 years of experience in technology and computer security to uncover the methods that computer hackers use to access information, and show students how not to be a victim. All courses are taught at a novice level that allows people from all educational and professional backgrounds to grasp the material.
The scheduled courses include; Computer Forensics, Computer Theft Prevention & Stolen Computer Recovery, Computer Surveillance and Spyware, Cyber Law - The Law of the Internet, Identity Theft Seminar, Password Cracking and Recovery, Security Policies, White Hat Hacking, and Wireless Security.
"I am very excited to partner with Appalachian Technical College. These are much needed courses for everyone," says CEO Gregory Evans. LIGATT Security's Cyber Crime courses are ideal for everyone. From people who understand that Cyber Crime is an ever increasing threat, to law enforcement officials who are accountable for protecting the personal information of the public, LIGATT Security's Cyber Crime courses will equip students with the knowledge to combat Cyber Crime. All courses are eligible for Peace Officer Standards and Training (POST) certification for law enforcement officials.
"We are thrilled about LIGATT Security's Cyber Crime courses because not only do they enhance our Criminal Justice program, but they also show Law Enforcement officials how to keep information secure," says Darrell Dial, Continuing Education Coordinator for Appalachian Technical College. "We chose LIGATT Security's courses in particular because they are very skilled in Computer Security and offer courses that cover a broad spectrum of Cyber Crime in detail, a topic that is pivotal for students in the current economic state."
Gregory Evans is a Certified Ethical Hacker and industry leader in Computer Security. Evans has successfully taught Cyber Crime courses at several colleges in the Los Angeles, California area. A few of these institutions include: Pepperdine University, Santa Monica College, and California State - Los Angeles campus.
LIGATT Security (IGTP) is a publicly traded company that specializes in Hi-Tech Security and continues to strive as a leader in Computer Security, CCTV Surveillance, and Cyber Crime investigation. For more information about LIGATT Security (IGTP), go to www.ligatt.com.
If you would like more information about the courses offered, or would like to register for a class, log on to www.appalachiantech.edu and click on continuing education. All courses are listed under the Crime Computer Security section.
Contact:
Melanie Banks
Public Relations Director
6050 Peachtree Pkwy
Suite 240-147
Norcross, GA 30092
866-354-4288 x5
pr@ligatt.com
www.ligatt.com
On December 23, 2008, Archemix Corp. ("Archemix") , which is a party to that certain agreement and plan of merger dated November 18, 2008 by and between Archemix, NitroMed, Inc. ("NitroMed"), and Newport Acquisition Corp., a wholly owned subsidiary of NitroMed, issued a press release announcing a strategic alliance with GlaxoSmithKline. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
IMPORTANT ADDITIONAL INFORMATION WILL BE FILED WITH THE SEC In connection with Archemix's proposed merger with NitroMed, Inc. ("NitroMed"), NitroMed has filed with the SEC a Registration Statement on Form S-4 containing a joint proxy statement/prospectus. Once the Form S-4 is declared effective by the SEC, the joint proxy statement/prospectus will be mailed to stockholders of NitroMed and Archemix. The joint proxy statement/prospectus will contain important information about NitroMed, Archemix, the transaction and related matters. In addition, NitroMed has filed with the SEC and mailed to its stockholders a definitive proxy statement in connection with the proposed sale of its BiDil? and BiDil XR? drug business to JHP Pharmaceuticals, LLC. The definitive proxy statement contains important information about NitroMed, the proposed sale of the BiDil and BiDil XR drug business and related matters. Investors and security holders of NitroMed and Archemix are urged to read carefully both the definitive proxy statement relating to the proposed sale of the BiDil and BiDil XR drug business and the joint proxy statement/prospectus relating to the merger (when it is available).
Investors and security holders of NitroMed are able to obtain free copies of the definitive proxy statement for the proposed sale of the BiDil and BiDil XR drug business and the joint proxy statement/prospectus for the proposed merger (when it is available), and other documents filed with the SEC by NitroMed through the website maintained by the SEC at www.sec.gov. In addition, investors and security holders of NitroMed are able to obtain free copies of the definitive proxy statement for the proposed sale of the BiDil and BiDil XR drug business and the joint proxy statement/prospectus for the proposed merger (when it is available) by contacting NitroMed, Inc., Attn: Secretary, 45 Hayden Avenue, Suite 3000, Lexington, MA 02421. Investors and security holders of Archemix will be able to obtain free copies of the joint proxy statement/prospectus for the merger (when it is available) by contacting Archemix Corp., Attn: Secretary, 300 Third Street, Cambridge, MA 02142.
NitroMed, and its directors and executive officers, may be deemed to be participants in the solicitation of proxies in respect of the transactions contemplated by the purchase and sale agreement with JHP Pharmaceuticals relating to the sale of the BiDil and BiDil XR drug business, and NitroMed and Archemix, and their respective directors and executive officers, may be deemed to be participants in the solicitation of proxies in respect of the transactions contemplated by the merger agreement with Archemix. Information regarding NitroMed's directors and executive officers is contained in NitroMed's Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and its proxy statement dated April 16, 2008, which are filed with the SEC, and in NitroMed's definitive proxy statement relating to the proposed sale of the BiDil and BiDil XR drug business, which was filed with the SEC on December 15, 2008. As of November 30, 2008, NitroMed's directors and executive officers, and funds affiliated with such individuals, owned approximately 33% of NitroMed's common stock. A more complete description of the interests of NitroMed's directors and officers is available in the definitive proxy statement relating to the sale of the BiDil and BiDil XR drug business. In addition, information regarding Archemix's
I think we jump to $0,045 today, Happy Christmas
Last Price (USD) $ 0.0007 Change ▲ 0.0003 (75.00%)
yeahh 0,09 today
XDSL Contract with PORSCHE !!!!!!!!!!!!!!!!!!!!!!!!!!!!!
8-Dec-2008
Entry into a Material Definitive Agreement, Financial Statements and Exhi
Item 1.01 Entry into a Material Definitive Agreement
On December 5, 2008 mPhase Technologies, Inc. signed a contract with Porsche Design Gesellschaft m.b.H., Flugplatzstrasse 29, A,S700 Zell am see. Austrla
["Porsche Design' Studio"], to design a premium version of the AlwaysReady Emergency Flashlight. The flashlight will contain mPhase's proprietary lithium reserve battery. The battery contains a breakable barrier that separates the solid electrodes from the liquid electrolyte until the battery is manually activated. Unlike traditional batteries, the mPhase battery remains in an inert state with no leakage or self-discharge until activation. The mPhase battery is designed to have an almost infinite shelf life making it ideal for emergency lighting applications.
The premium flashlight will be marketed as an accessory for automobile roadside emergency kits.
Item 9.01 Financial Statements and Exhibits
The Company has, pursuant to Rule 24 (b-2) of the Securities Exchange Act of 1934, as amended, requested Confidential Treatment for the above contract.
Contract with PORSCHE !!!!!!!!!!!!!!!!!!!!!!!!!!!!!
8-Dec-2008
Entry into a Material Definitive Agreement, Financial Statements and Exhi
Item 1.01 Entry into a Material Definitive Agreement
On December 5, 2008 mPhase Technologies, Inc. signed a contract with Porsche Design Gesellschaft m.b.H., Flugplatzstrasse 29, A,S700 Zell am see. Austrla
["Porsche Design' Studio"], to design a premium version of the AlwaysReady Emergency Flashlight. The flashlight will contain mPhase's proprietary lithium reserve battery. The battery contains a breakable barrier that separates the solid electrodes from the liquid electrolyte until the battery is manually activated. Unlike traditional batteries, the mPhase battery remains in an inert state with no leakage or self-discharge until activation. The mPhase battery is designed to have an almost infinite shelf life making it ideal for emergency lighting applications.
The premium flashlight will be marketed as an accessory for automobile roadside emergency kits.
Item 9.01 Financial Statements and Exhibits
The Company has, pursuant to Rule 24 (b-2) of the Securities Exchange Act of 1934, as amended, requested Confidential Treatment for the above contract.
Mphase Techs (BB) (XDSL)▲$0.04Change:0.0255 (175.86%)Volume:15,069,21615:59:09 ESTDec-5-08
Mphase Techs (BB) (XDSL)▲$0.04Change:0.0255 (175.86%)Volume:15,069,21615:59:09 ESTDec-5-08
Mphase Techs (BB) (XDSL)▲$0.04Change:0.0255 (175.86%)Volume:15,069,21615:59:09 ESTDec-5-08
Next Week 0,12 $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
XDSl UUPP 110% many VOl.
UUUPPP 110% with a many Vol.
10 Bagger!!!!!!!!!!!!!!from now
Barclays May Walk Away From Lehman ETNs >BCS LEHMQLast update: 9/24/2008 11:25:09 AM
Barclays May Walk Away From Lehman ETNs >BCS LEHMQLast update: 9/24/2008 11:25:09 AM
Expert Group, Inc. Retains MG Studios to Launch New Television Commercial Campaign
MIAMI, FL -- (Marketwire) -- 09/24/08 -- Expert Group, Inc. (PINKSHEETS: EXPT) is pleased to announce that the Company has contracted the services of MG Studios in Longwood, Florida to produce a television commercial advertising the Company's services. The 30-second spot will be broadcast in English and Spanish and will air in Southern Florida, aimed at creating brand awareness as well as targeting prospective homebuyers.
Expert Group is committed to establishing its name as the foremost source of residential and commercial loans. It hired MG Studios for its extensive experience producing strikingly effective commercials with maximum impact on the target viewership. The commercial will air later this year and will immediately increase awareness of the services that Expert Group's subsidiaries provide. The commercial will concisely demonstrate its services and entice potential home owners to pursue mortgages and remain optimistic about the current market.
"The Expert Group came to us with a brilliantly organized marketing campaign and we expect to convert their vision into reality as they vigorously approach the South Florida mortgage and real estate markets," stated Mike Gibilisco, CEO of MG Studios, Inc.
About MG Studios, Inc.:
MG Studios is a full-service production facility that provides a variety of services for commercials, infomercials and television shows. MG Studios works with major television and movie companies in the United States. Some of the services that MG Studios provides include writing, editing and production for media content such as film, animation, 3D graphics and music videos. For more information about MG Studios, please visit the following link: www.mgstudios.com.
About Expert Group, Inc.:
Expert Group, Inc. markets a variety of financial products and services through Expert Financing & Inv. Inc., which offers loan programs tailored to all borrowers' needs, specializing in Fannie Mae, Freddie Mac, FHA, conventional and non-conventional loans of all sizes and Expert Credit Fix U.S.A., assisting borrowers with less than perfect credit to restore their credit to a level where lenders will grant them credit. Expert is licensed by the Department of Financial Regulations and a member of FAMB, and since inception has originated over 100 million in real estate loans.
Certain statements in this release and the attached corporate profile that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by the use of words such as anticipate, believe, expect, future, may, will, would, should, plan, projected, intend and similar expressions. Such statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including but not limited to the Company's ability to: (I) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; and (iv) other risk factors.
Contact:
Expert Group, Inc.